Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma
40 patients with advanced non-small cell lung cancer not previously treated were included in a study at phase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 each 28 days for 6 cycles. There were 31 men and 9 women, being the average age of 5...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Español |
| Publicado: |
1995
|
| Materias: | |
| Acceso en línea: | http://pa.bibdigital.ucc.edu.ar/3717/1/A_Richardet_Carranza_Uribe_Tolocka_Cresta_Uribe_Uribe.pdf |
| Aporte de: |
| Sumario: | 40 patients with advanced non-small cell lung cancer not previously treated were included in a study at phase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 each 28 days for 6 cycles. There were 31 men and 9 women, being the average age of 54 years, with "performance Status" grade 0-2. All of them could be evaluated for toxicity and 31 for responsiveness. 10 patients were in stage IIIb and 21 at stage IV. 42% of objective responses were obtained and an overall survival of 9 months, which justifies further studies. |
|---|